3D Medicines (HKSE:01244) Construction In Progress : HK$124.6 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines Construction In Progress?

3D Medicines's quarterly construction in progress declined from Dec. 2022 (HK$113.2 Mil) to Jun. 2023 (HK$0.0 Mil) but then increased from Jun. 2023 (HK$0.0 Mil) to Dec. 2023 (HK$124.6 Mil).

3D Medicines's annual construction in progress increased from Dec. 2021 (HK$35.8 Mil) to Dec. 2022 (HK$113.2 Mil) and increased from Dec. 2022 (HK$113.2 Mil) to Dec. 2023 (HK$124.6 Mil).

3D Medicines Construction In Progress Historical Data

The historical data trend for 3D Medicines's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines Construction In Progress Chart

3D Medicines Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Construction In Progress

35.78

113.22

124.64

3D Medicines Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Construction In Progress	Get a 7-Day Free Trial			35.78	-	113.22	-	124.64

3D Medicines Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

3D Medicines (HKSE:01244) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN

Website

https://www.3d-medicines.com

3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.

Executives

Gong Zhaolong	2101 Beneficial owner
Zhu Pai	2101 Beneficial owner
Dragon Prosper Holdings Limited	2101 Beneficial owner
Simcere Pharmaceutical Group Limited	2101 Beneficial owner
Gong Zhaolong	2501 Other
Immunal Medixin Us Limited	2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership)	2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd.	2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.)	2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership)	2201 Interest of corporation controlled by you
Zhu Jinqiao	2103 Interests held jointly with another person

3D Medicines (HKSE:01244) Headlines

No Headlines